ArticleCancers2022

The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer.

Christopher B Nahm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.